The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Zhou, S., Schuetz, J. D., Bunting, K. D., Colapietro, A.-M., Sampath, J., Morris, J. J., Lagutina, I., Grosveld, G. C., Osawa, M., Nakauchi, H., et al. (2001) · Nature Medicine · doi:10.1038/nm0901-1028 · Cited by 2,280
Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040258 · Cited by 1,485
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
The development of imatinib as a therapeutic agent for chronic myeloid leukemia
Deininger, M., Buchdunger, E., & Druker, B. J. (2005) · Blood · doi:10.1182/blood-2004-08-3097 · Cited by 1,253
Hughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Graham, S. M., Jørgensen, H. G., Allan, E., Pearson, C., Alcorn, M. J., Richmond, L., & Holyoake, T. L. (2002) · Blood · doi:10.1182/blood.v99.1.319 · Cited by 1,181
Chronic Myeloid Leukemia — Advances in Biology and New Approaches to Treatment
Goldman, J. M., & Melo, J. V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020777 · Cited by 950
Scharenberg, C. W., Harkey, M. A., & Torok-Storb, B. (2002) · Blood · doi:10.1182/blood.v99.2.507 · Cited by 770
Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 765
Active transport of imatinib into and out of cells: implications for drug resistance
Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 643
Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
Mahon, F.-X., Belloc, F., Lagarde, V., Chollet, C., Moreau-Gaudry, F., Reiffers, J., Goldman, J. M., & Melo, J. V. (2003) · Blood · doi:10.1182/blood.v101.6.2368 · Cited by 538
Holyoake, T., Jiang, X., Eaves, C., & Eaves, A. (1999) · Blood · doi:10.1182/blood.v94.6.2056 · Cited by 515
Self-citationLi, S., Ilaria, R. L., Million, R. P., Daley, G. Q., & Van Etten, R. A. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1399 · Cited by 501
White, D. L., Saunders, V. A., Dang, P., Engler, J., Zannettino, A. C. W., Cambareri, A. C., Quinn, S. R., Manley, P. W., & Hughes, T. P. (2006) · Blood · doi:10.1182/blood-2005-11-4687 · Cited by 435
Burger, H., van Tol, H., Boersma, A. W. M., Brok, M., Wiemer, E. A. C., Stoter, G., & Nooter, K. (2004) · Blood · doi:10.1182/blood-2004-04-1398 · Cited by 417
High-Affinity Interaction of Tyrosine Kinase Inhibitors with the ABCG2 Multidrug Transporter
Özvegy-Laczka, C., Hegedűs, T., Várady, G., Ujhelly, O., Schuetz, J. D., Váradi, A., Kéri, G., Őrfi, L., Német, K., & Sarkadi, B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.6.1485 · Cited by 340
Holtz, M. S., Slovak, M. L., Zhang, F., Sawyers, C. L., Forman, S. J., & Bhatia, R. (2002) · Blood · doi:10.1182/blood.v99.10.3792 · Cited by 253
Jiang, X., Lopez, A., Holyoake, T., Eaves, A., & Eaves, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12804 · Cited by 227
Self-citationChu, S., Xu, H., Shah, N. P., Snyder, D. S., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2005) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 209
Hogge, D., Lansdorp, P., Reid, D., Gerhard, B., & Eaves, C. (1996) · Blood · doi:10.1182/blood.v88.10.3765.bloodjournal88103765 · Cited by 207
Self-citationBurger, H., van Tol, H., Brok, M., Wiemer, E. A. C., de Bruijn, E. A., Guetens, G., de Boeck, G., Sparreboom, A., Verweij, J., & Nooter, K. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.7.1826 · Cited by 207
hOCT 1 and resistance to imatinib
Crossman, L. C., Druker, B. J., & Deininger, M. W. N. (2005) · Blood · doi:10.1182/blood-2005-02-0694 · Cited by 206
Barnes, D. J., Palaiologou, D., Panousopoulou, E., Schultheis, B., Yong, A. S. M., Wong, A., Pattacini, L., Goldman, J. M., & Melo, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0076 · Cited by 200
Tyrosine phosphorylation of CRKL in Philadelphia+ leukemia
ten Hoeve, J., Arlinghaus, R., Guo, J., Heisterkamp, N., & Groffen, J. (1994) · Blood · doi:10.1182/blood.v84.6.1731.1731 · Cited by 183
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L., & Mountford, J. C. (2006) · Blood · doi:10.1182/blood-2006-02-003145 · Cited by 158
Holyoake, T. L., Jiang, X., Jørgensen, H. G., Graham, S. M., Alcorn, M. J., Laird, C., Eaves, A. C., & Eaves, C. J. (2001) · Blood · doi:10.1182/blood.v97.3.720 · Cited by 152
Self-citationLepper, E. R., Nooter, K., Verweij, J., Acharya, M. R., Figg, W. D., & Sparreboom, A. (2005) · Pharmacogenomics · doi:10.1517/14622416.6.2.115 · Cited by 142
Holyoake, T. L., Jiang, X., Drummond, M. W., Eaves, A., & Eaves, C. J. (2002) · Leukemia · doi:10.1038/sj.leu.2402444 · Cited by 139
Self-citationFusion tyrosine kinases: a result and cause of genomic instability
Penserga, E. T. P., & Skórski, T. (2006) · Oncogene · doi:10.1038/sj.onc.1209756 · Cited by 82
Hamilton, A., Elrick, L. J., Myssina, S., Copland, M., Jørgensen, H. G., Melo, J. V., & Holyoake, T. L. (2006) · Leukemia · doi:10.1038/sj.leu.2404189 · Cited by 81
Jiang, X., Zhao, Y. S., Chan, W. Y., Vercauteren, S., Pang, E., Kennedy, S., Nicolini, F., Eaves, A. C., & Eaves, C. J. (2004) · Blood · doi:10.1182/blood-2003-11-4026 · Cited by 49
Self-citationFluorodeoxyuridine synchronization of hemopoietic colonies
Fraser, C., Eaves, C. J., & Kalousek, D. K. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90077-x · Cited by 27
Self-citationDugray, A., Geay, J., Foudi, A., Bonnet, M., Vainchenker, W., Wendling, F., Louache, F., & Turhan, A. G. (2001) · Leukemia · doi:10.1038/sj.leu.2402225 · Cited by 26
Self-citationJiang, X., Fujisaki, T., Nicolini, F. E., Berger, M. G., Holyoake, T. L., Eisterer, W., Eaves, C. J., & Eaves, A. (2000) · Leukemia · doi:10.1038/sj.leu.2401752 · Cited by 21
Self-citationChalandon, Y., Jiang, X., Loutet, S. A., Eaves, A. C., & Eaves, C. J. (2004) · Leukemia · doi:10.1038/sj.leu.2403335 · Cited by 11
Self-citation
Cited by
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,446
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás-Cardama, A., & Cortes, J. (2009) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 745
Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update
Mao, Q., & Unadkat, J. D. (2015) · The AAPS Journal · doi:10.1208/s12248-014-9668-6 · Cited by 670
Metadata
- Authors
- Jiang, X., Zhao, Y., Smith, C., Gasparetto, M., Turhan, A., Eaves, A., & Eaves, C.
- Venue
- Leukemia
- Published
- 2007-03-01
- Volume
- 21
- Issue
- 5
- Pages
- 926-935
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W2012153991
- Cited by
- 359
- References
- 46
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.